EA199800391A1 - Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору - Google Patents

Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору

Info

Publication number
EA199800391A1
EA199800391A1 EA199800391A EA199800391A EA199800391A1 EA 199800391 A1 EA199800391 A1 EA 199800391A1 EA 199800391 A EA199800391 A EA 199800391A EA 199800391 A EA199800391 A EA 199800391A EA 199800391 A1 EA199800391 A1 EA 199800391A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
inhibition
tumor growth
antisense oligonucleotides
oligonucleotides
Prior art date
Application number
EA199800391A
Other languages
English (en)
Other versions
EA000841B1 (ru
Inventor
Збигньев Пьетрзковски
Дарьюс Сьеслак
Гордана Олбайна
Original Assignee
Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ filed Critical Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ
Publication of EA199800391A1 publication Critical patent/EA199800391A1/ru
Publication of EA000841B1 publication Critical patent/EA000841B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Приводятся олигонуклеотиды, эффективно ингибирующие рост, метастазирование и/или ангиогенез при опухолях, включая, в частности, меланому и/или другие виды рака. Также приводятся способы применения этих олигонуклеотидов для лечения заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800391A 1995-11-21 1996-11-16 Антисмысловые олигонуклеотиды к ил-8 и рецептору ил-8 и способ лечения злокачественных опухолей EA000841B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56130295A 1995-11-21 1995-11-21
PCT/US1996/018406 WO1997019097A1 (en) 1995-11-21 1996-11-16 Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor

Publications (2)

Publication Number Publication Date
EA199800391A1 true EA199800391A1 (ru) 1999-10-28
EA000841B1 EA000841B1 (ru) 2000-04-24

Family

ID=24241411

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800391A EA000841B1 (ru) 1995-11-21 1996-11-16 Антисмысловые олигонуклеотиды к ил-8 и рецептору ил-8 и способ лечения злокачественных опухолей

Country Status (14)

Country Link
US (2) US5849903A (ru)
EP (1) EP0879241A4 (ru)
JP (1) JPH11507245A (ru)
KR (1) KR19990071523A (ru)
CN (1) CN1202900A (ru)
AU (1) AU708096B2 (ru)
CA (1) CA2236825A1 (ru)
CZ (1) CZ154898A3 (ru)
EA (1) EA000841B1 (ru)
MX (1) MX9804009A (ru)
PL (1) PL326674A1 (ru)
SI (1) SI9620122A (ru)
SK (1) SK66098A3 (ru)
WO (1) WO1997019097A1 (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
KR100530278B1 (ko) * 1997-02-28 2006-04-06 동국제약 주식회사 아시아트산 유도체를 유효성분으로 하는 간 보호 및치료제
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
DK1045918T3 (da) 1998-01-12 2008-12-08 Pedro Jose G protein-relaterede kinasemutanter i essentiel hypertension
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
IL140054A0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
MXPA02005842A (es) * 1999-12-13 2003-10-14 Bioniche Life Sciences Inc Oligonucleotidos sinteticos terapeuticamente utiles.
WO2001047518A1 (en) * 1999-12-23 2001-07-05 Childrens Hospital Los Angeles Research Institute Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
US9012417B2 (en) * 2001-02-20 2015-04-21 Anges Mg, Inc. Topical administration of NF-kappaB decoy to treat atopic dermatitis
US20030207834A1 (en) * 2001-07-10 2003-11-06 Dale Roderic M.K. Oligonucleotide-containing pharmacological compositions and their use
EP2311852A1 (en) 2002-02-06 2011-04-20 Stasys Technologies, Inc. Anti-infarction molecules
WO2003093452A2 (en) * 2002-02-26 2003-11-13 University Of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
WO2004013160A2 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
CN100537761C (zh) * 2003-11-07 2009-09-09 中国人民解放军军事医学科学院放射医学研究所 反义寡核苷酸,含它们的药物组合及其用于治疗癌症的用途
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US7994130B2 (en) 2006-12-11 2011-08-09 University Of Utah Research Foundation Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
CN101275134B (zh) * 2007-04-20 2010-06-02 清华大学深圳研究生院 治疗乳腺癌的药物及其专用反义寡核苷酸
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
EP2853897A1 (en) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2010019963A2 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
US10441637B2 (en) 2013-11-21 2019-10-15 Sena Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
DK3491014T3 (da) 2016-07-28 2023-05-30 Regeneron Pharma Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant
KR20190037273A (ko) 2016-08-03 2019-04-05 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Tlr9 표적 치료제
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
SG11201911597YA (en) 2017-06-05 2020-01-30 Regeneron Pharma B4galt1 variants and uses thereof
SG11202001754RA (en) 2017-09-06 2020-03-30 Regeneron Pharma Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
SG11202001792UA (en) 2017-09-07 2020-03-30 Regeneron Pharma Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
JP2021501601A (ja) 2017-10-16 2021-01-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． コルヌリン（ｃｒｎｎ）バリアント及びその使用
US10752682B2 (en) 2017-11-01 2020-08-25 Nantbio, Inc. Anti-IL8 antibodies
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides

Also Published As

Publication number Publication date
AU708096B2 (en) 1999-07-29
CN1202900A (zh) 1998-12-23
JPH11507245A (ja) 1999-06-29
EP0879241A1 (en) 1998-11-25
KR19990071523A (ko) 1999-09-27
EP0879241A4 (en) 2000-04-19
CA2236825A1 (en) 1997-05-29
SI9620122A (sl) 1999-04-30
SK66098A3 (en) 1998-11-04
PL326674A1 (en) 1998-10-12
US6017898A (en) 2000-01-25
AU1053197A (en) 1997-06-11
MX9804009A (es) 1998-11-29
EA000841B1 (ru) 2000-04-24
US5849903A (en) 1998-12-15
WO1997019097A1 (en) 1997-05-29
CZ154898A3 (cs) 1998-09-16

Similar Documents

Publication Publication Date Title
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
DE986382T1 (de) Raf kinase hemmer
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
DK0988301T3 (da) Imidazolylcykliske acetaler
CY1105395T1 (el) Αναστολη της raf κινασης χρησιμοποιωντας αρυλικες και ετepοαρυλικες υποκατεστημενες ετepοκυκλικες ουριες
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
DE3888378T2 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
NO974943L (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
DE69128543T2 (de) Monoklonale antikörper der maus
EA200300525A1 (ru) Гликозидирование индолкарбазола с применением межфазного катализа
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ATE234354T1 (de) Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind.
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
SU1540072A1 (ru) Способ лечения рака прямой кишки

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU